Shang-Ying Hu1,2, Sabrina H Tsang2, Feng Chen1, Qin-Jing Pan3, Wen-Hua Zhang4, Ying Hong5, Joshua N Sampson2, Allan Hildesheim2, Fang-Hui Zhao1, Aimée R Kreimer2. 1. Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. 3. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 4. Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 5. Department of Obstetrics and Gynecology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.
Abstract
BACKGROUND: How vaginal infections such as bacterial vaginosis, Candida spp, and Trichomonas vaginalis affect persistence of human papillomavirus (HPV) infection is not well established. Our study aimed to evaluate the association between common vaginal infections and cervical non-HPV16/18 infection, as risk factors associated with persistence of nonvaccine HPV types will become increasingly relevant in the setting of HPV vaccination. METHODS: We performed an analysis in 2039 AS04-HPV16/18-vaccinated women enrolled in a phase II/III trial in China, who were HPV DNA negative at month 0 and 6 and had at least 1 subsequent follow-up visit. Vaginal infections were detected in liquid-based cytology according to the diagnostic criteria of the Bethesda System. Associations between vaginal infections and incident and 6-month persistent non-HPV16/18 infections in the cervix were evaluated using generalized estimating equations, adjusting for the age at initial vaccination, as well as HPV types in the persistence analysis. RESULTS: Study visits with any vaginal infection had a statistically significant increased risk of incident non-HPV16/18 infection compared to those without vaginal infections (odds ratio [OR], 1.44 [95% confidence interval {CI}, 1.09-1.92]). However, vaginal infections were not associated with 6-month persistent non-HPV16/18 infection (OR, 1.02 [95% CI, .62-1.69]). CONCLUSIONS: Our study suggests that common vaginal infections are not associated with persistence of non-HPV16/18 infection among HPV16/18-vaccinated women.
BACKGROUND: How vaginal infections such as bacterial vaginosis, Candida spp, and Trichomonas vaginalis affect persistence of human papillomavirus (HPV) infection is not well established. Our study aimed to evaluate the association between common vaginal infections and cervical non-HPV16/18 infection, as risk factors associated with persistence of nonvaccine HPV types will become increasingly relevant in the setting of HPV vaccination. METHODS: We performed an analysis in 2039 AS04-HPV16/18-vaccinated women enrolled in a phase II/III trial in China, who were HPV DNA negative at month 0 and 6 and had at least 1 subsequent follow-up visit. Vaginal infections were detected in liquid-based cytology according to the diagnostic criteria of the Bethesda System. Associations between vaginal infections and incident and 6-month persistent non-HPV16/18 infections in the cervix were evaluated using generalized estimating equations, adjusting for the age at initial vaccination, as well as HPV types in the persistence analysis. RESULTS: Study visits with any vaginal infection had a statistically significant increased risk of incident non-HPV16/18 infection compared to those without vaginal infections (odds ratio [OR], 1.44 [95% confidence interval {CI}, 1.09-1.92]). However, vaginal infections were not associated with 6-month persistent non-HPV16/18 infection (OR, 1.02 [95% CI, .62-1.69]). CONCLUSIONS: Our study suggests that common vaginal infections are not associated with persistence of non-HPV16/18 infection among HPV16/18-vaccinated women.
Authors: Rachel L Winer; James P Hughes; Qinghua Feng; Long Fu Xi; Stephen Cherne; Sandra O'Reilly; Nancy B Kiviat; Laura A Koutsky Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-12-20 Impact factor: 4.254
Authors: Gweneth B Lazenby; Peyton T Taylor; Barbara S Badman; Emil McHaki; Jeffrey E Korte; David E Soper; Jennifer Young Pierce Journal: Clin Ther Date: 2014-01-01 Impact factor: 3.393
Authors: P E Castle; S L Hillier; L K Rabe; A Hildesheim; R Herrero; M C Bratti; M E Sherman; R D Burk; A C Rodriguez; M Alfaro; M L Hutchinson; J Morales; M Schiffman Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-10 Impact factor: 4.254
Authors: Matti Lehtinen; Kevin A Ault; Erika Lyytikainen; Joakim Dillner; Suzanne M Garland; Daron G Ferris; Laura A Koutsky; Heather L Sings; Shuang Lu; Richard M Haupt; Jorma Paavonen Journal: Sex Transm Infect Date: 2011-04-06 Impact factor: 3.519
Authors: Anita Mitra; David A MacIntyre; Julian R Marchesi; Yun S Lee; Phillip R Bennett; Maria Kyrgiou Journal: Microbiome Date: 2016-11-01 Impact factor: 14.650